


Beck et al. *N Engl J Med.* 2014 Jul 10;371(2):130-9

Clinical Update: Dupilumab

- ☐ Moderate-to-severe atopic dermatitis (AD): intractable pruritus associated with sleep disturbance and lower quality-of-life
- ☐T-helper 2 (TH2) inflammation mediates many features of AD
 - □ Regulated by IL-4 and IL-13

Beck et al. N Engl J Med. 2014 Jul 10;371(2):130-9

Dupilumab (anti-IL-4Rα) blocks the IL-4/IL-13 receptor/ligand system



Type I Receptor

B cells, T cells, Monocytes, Eosinophils, Fibroblasts

Type II Receptor

Epithelial cells, Smooth muscle cells, Fibroblasts, Monocytes, Activated B cells